Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.36 - $2.29 $11,832 - $19,923
8,700 Added 129.85%
15,400 $28,000
Q1 2024

May 15, 2024

SELL
$1.76 - $2.41 $51,920 - $71,095
-29,500 Reduced 81.49%
6,700 $11,000
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.92 $20,628 - $36,672
19,100 Added 111.7%
36,200 $63,000
Q3 2023

Nov 14, 2023

SELL
$1.41 - $2.97 $6,345 - $13,365
-4,500 Reduced 20.83%
17,100 $24,000
Q2 2023

Aug 14, 2023

BUY
$1.0 - $3.86 $21,600 - $83,376
21,600 New
21,600 $49,000
Q4 2022

Feb 14, 2023

BUY
$0.74 - $1.04 $814 - $1,144
1,100 New
1,100 $0

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.